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SUMMARY.-Dosage recommendations for cyclophosphamide therapy are
examined in the light of an accumulated experience that this agent provides a
useful palliation in 25% to 35% of patients with advanced breast cancer. It is
concluded that an attempt to press dosage to the extreme limits of marrow
tolerance does not significantly increase the likelihood of obtaining palliation,
while posing a danger to the patient's life.
It is also concluded that continuous low dosage schedules appear to achieve
a similar incidence of tumour palliation to that from intermittent high dosage
of cyclophosphamide. The latter schedule has the disadvantage of a consider-
ably higher incidence of side effects, such as loss of scalp hair, nausea, cystitis
and haemopoietic damage. Intensive dosage may however be more efficacious
in the occasional case involving urgent management of a localized rapidly
growing tumour. Consideration is given to other factors which may affect
the degree and duration of palliation by cyclophosphamide, and to measures
claimed to decrease the degree oftoxicity.
CYCLOPHOSPHAMIDE is probably the most widely used ofthe alkylating agents
in the chemotherapy of late breast cancer. There is no claim of anything more
than short term control by this agent in breast cancer and it is therefore essential
to distinguish between dosage schedules aimed at cure from those aimed at
temporarygrowth restraint.
When a new cytotoxic agent is introduced, the dosage schedule is, in general,
established upon its capacity to eradicate tumour growth in animals. In its
subsequent clinical trials in humans, dosage may be pushed to maximum toxicity
levels in order to assess its therapeutic potential. However, when this has been
realistically established as palliative, the dosage regime should aim to achieve the
maximum incidence, degree, and duration oftumour regression compatible with a
minimum degree of toxicity.
In this connection, it may not be generally appreciated that failure by an agent
to achieve clinical evidence of tumour regression is not necessarily evidence of
complete tumour autonomy with respect to that agent. A cytostatic agent which
is capable of completely stopping cell division in a tumour, will not reduce the
size of the tumour unless spontaneous cell loss is taking place at the same time.
Ifgross tumour regression is to occur, the adult cells must, in addition, be damaged
by the agent, and this may take a considerable time to be manifested (Bagshawe,
1968). Furthermore, with intermittent drug administration, evidence of tumour
remission may not be established if toxicity prevents the repeat dose being given
beforethe tumourhas regrown to its original size (Bergsagel, 1969). A sub-clinical
effect on tumour growth is possible without significant regression ofvisible lesions.
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Dosage schedules in cyclophosphamide therapy
The difference between curative and palliative aims may involve quite different
dosage schedules ofcytotoxic therapy.
On theoretical grounds, cure of a rapidly growing tumour is more likely to
follow intermittent high dose cyclophosphamide therapy, providing a high drug
concentration in the part over a short period (Bergsagel, 1969). Such a dosage
schedule may also be useful in achieving dramatic regression of a localized but
rapidly growingtumourwhichis causing dangerous pressure symptoms. However,
the risk ofsevere marrow damage from such intensive high dose therapy precludes,
or considerably delays, subsequent maintenance therapy for tumour growth
restraint. The continuous low dose schedule (usually after a priming dose) may
theoretically be more useful in restraining IDNA synthesis or mitosis in a slowly
dividing tumour. It is certainly safer in the case ofa widely disseminated tumour
with extensive liver or bone marrow involvement.
There are no claims in the literature of cure of breast cancer as a result of
cyclophosphamide therapy. With regard to palliation, there are considerable
differences in the dosage regimes reported for the use of cyclophosphamide, but
no reports which suggest selection of dosage according to the criteria mentioned
above.
The dosage schedule in cyclophosphamide therapy may be important not only
in determining the percentage incidence, degree and duration of tumour control,
but also in determining the type and degree oftoxic effects. In this latter respect,
the use of cyclophosphamide therapy involves specific problems, for whereas
evidence of severe haematological toxicity may cause anxiety to the physician, it
is the degree of alopecia, or the severity of nausea and vomiting, which causes the
greater concern to a woman already suffering physically and psychologically from
the manifestation oflate breast cancer. The not uncommon statement, in regard
to cyclophosphamide therapy, that temporary alopecia does not disturb women
patients unduly, merely indicates that the choice ofan alternative therapy has not
been offered by the physician.
Dosage schedule in relation to toxicity
Intermittent high dosage by cyclophosphamide 50 mg./kg. intravenously is
followed by some degree of alopecia in 100% of patients, loss of scalp hair being
almost complete in halfthe cases (Stoll and Matar, 1961). The incidence ofalopecia
falls to about 5000 either with intermittent dosage of 15 mg./kg. weekly (Shnider,
1962) or with a total dosage of 50 mg./kg. spread over 3 to 4 weeks (Anders, 1964),
and in these cases it is usually of minimal degree.
Following the initial high dose, epilation is maximal at 2 months and the hair
usually beings to regrow at 3 months, although alopecia may recur after subse-
quent high doses. In occasional cases the scalp hair which regrows may be
permanently changed in character or stunted. With continuous low dosage of
2 mg./kg daily, a slight falling of scalp hair may be the first sign of toxicity in our
experience and may occur even when the peripheral blood count is still normal.
Following intermittent high dosage, depression ofthe peripheral leucocyte and
platelet levels is maximal after 7 to 13 days (Stoll and Matar, 1961), and the
effects on leucocytes and platelets tend to run parallel. In the case of continuous
low dosage, the earliest fall in leucocyte level usually occurs after 14 to 28 days
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and is usually 7 to 14 days earlier than that of the platelet level. As a result,
severe thrombocytopenia can be avoided in such cases by careful watch on the
leucocyte level. If the marrow has not been damaged by malignant infiltration
or by previous cytotoxic therapy, it is usually possible to control continuous low
dosage therapy by fortnightly leucocyte counts without repeated platelet counts.
Permanant marrow depression has been reported after a total dosage of 20 to
40 g. of cyclophosphamide in 3 to 6 months (Betteridge 1964), but it is rarely seen
unless the marrow has been severely damaged by metastastic deposits, or by
previous cytotoxic therapy. When the marrow reserve is permanently depleted,
it is associated with depression of the reticulocyte response. Depression of
lymphocyte production is said to be associated with depression of immune mech-
anisms which may play an important part in tumour control by the body
(Southam, 1965). In this connection, high doses of cyclophosphamide have been
shown to decrease resistance to metastastic spread from rat tumours (Schmahl,
1963).
Intermittent high dosage of cyclophosphamide 50 mg./kg. intravenously is
associated with nausea and vomiting in over 7500 of patients (Stoll and Matar.
1961). Shnider (1962) in a comparison of dosage schedules, reported that these
symptoms were not troublesome until cyclophosphamide dosage exceeded
10 mg./kg. daily orally or 20 mg./kg. weekly intravenously. Although it is said
that patients on oral maintenance dosage become increasingly intolerant of the
drug's side effects (Cran, 1968), severe alopecia, or nausea and vomiting have been
rare in our experience in patients maintained on continuous dosage of 2 mg./kg.
daily orally, even for periods of between 1 and 2 years.
To summarize, therefore, it is generally agreed that toxic effects of all types
are more frequent from intermittent high doses of cyclophosphamide than from
continuous low dosage.
Dosageschedule in relation to tumnour palliation
Table I records in chronological order the major reports in the literature to
show the percentage remission rate in advanced breast cancer following cyclo-
TABLE I. Major Reports in Literature Showing Percentage Response in Advanced
Breast Cancer to Cyclophosphamide Therapy. In Chronological Order and
Technique of Drug Administration Noted
Cases Percentage
Author reportedi response Dosagetechnique
Stoll ai(1 Matar (1961) 20 35 Itermittenit high
Andersand Kemp(1961) 20 30 Continuous low
Cogginsetal.(1961) . 33 21 Either
Pommatauetal. (1961) 33 20-71* Either
Hurley et al. (1961) 39 59 Unspecified
Gerhartz (1964) 49 40 Either Gor(lon and McArthur (1965) 24 62*5 . Continuous low
Talleyetal.(1965) 62 22 . Continuous low
Cittadini (1966) 23 83 Iitermittent high
Snyman(1967) . 109 66 Unspecified
Forrest (1967) 76 50 Unspecified
Gebhardt (1967) 36 28 Intermittent high
Pigatto (1967) 43 84 Intermittent high Edelstyn etal.(1968) 58 48 Continiouis low
* According to whether" goo(l or" excellent" response.
477B. A. STOLL
phosphamide therapy. The remission rate varies between 21% and 84% but is
not related to the schedule of drug administration. The wide range in response
rate is related to the fact that criteria of response vary considerably between
different observers. To demonstrate this, Pommatau et al. (1961) have reported
remission rates ofeither 20% or 71% from cyclophosphamide therapy in the same
series of patients with breast cancer, according to whether the response was
classified as " excellent " or " good ". It is obvious that a comparison of dose
schedules canbe made only bythe same observer, and especially by trial oftherapy
on a random selection basis.
This has been done by Coggins et al. (1961) in a series of patients with breast
cancer. One group was given intermittent high dose therapy of 45-80 mg./kg.
intravenously at monthly intervals and the other was given an approximately
equivalent total dosage by continuous maintenance therapy of 50-150 mg. orally
daily after a priming dose of 4-6 daily intravenous injections of 7-5 mg./kg.
Cyclophosphamide treatment was continued either until the disease showed
progression, or until toxicity stopped treatment. There was no significant differ-
ence between the tumour regression rates or the duration of remission resulting
from the two methods, although 80% of the group given intermittent high dose
therapy showed a profound leukopenia as against only 37% of the group given
continuous low dose therapy.
A comparison of dose schedules was also reported by Bock et al. (1967) in
283 cases of various types of cancer. Intermittent high dosage of cyclophos-
phamide 30 mg./kg. was compared with continuous low dosage of 3 mg./kg. daily.
It was found in the case ofbreast cancer that continuous low dose therapy led not
only to a lower incidence of toxic effects, but also to a higher tumour regression
rate, and a longer average survival time.
In spite ofthe firm evidence provided by these reported trials, the use ofinter-
mittent high dosage of cyclophosphamide, often referred to as " shock " therapy
is still favoured by many in the palliation of disseminated breast cancer (Table I).
Effect of other factors on tumour palliation
Although this paper is mainly concerned with size ofdose and its fractionation,
there are other factors which may affect the degree and duration of palliation by
cyclophosphamide in any individual case of breast cancer
If the mitotic cycle of a tissue is short, then the response to cytotoxic agents
is more quickly manifest. Thus the clinical response to cyclophosphamide of an
anaplastic carcinoma of the breast usually appears sooner than does that of a
slowly growing scirrhous carcinoma. Regrowth of the tumour is also corres-
pondingly rapid in the former case.
Secondly, it is clinically well recognized that cytotoxic agents are less effective
in the presence oflarge masses oftumour, and that smaller tumours undergo more
complete regression than do larger tumours in the same patient. A possible
reason is that the larger tumour has a greater number ofadult cells to be damaged
before decrease in size can be manifested clinically. In experimental animals also,
it has been established (Skipper et al., 1957) that the smaller the colony of malig-
nant cells the better the response to cyctotoxic chemotherapy.
It is possible too that in the body there is a competitive uptake of the agent,
so that as the total mass of malignant tissue increases, so from any given dosage
the effective dosage to each tumour cell is decreased. Ablation oflarge masses of
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tumour has therefore been suggested before cytotoxic chemotherapy, in order to
increase the concentration from a palliative dose upon the remaining tumour.
A further explanation for the lesser response ofthe larger tumour is that it has
outgrown its blood supply, and its centre is poorly vascularized. For a similar
reason, previous irradiation of the part decreases the likelihood of a response to
cytotoxic chemotherapy, as the resultant fibrosis considerably decreases the
tumour's blood supply. This has been demonstrated experimentally in rats in
the case of transplanted tumours, treated by radiation before cyclophosphamide
administration (de Rochemont et al., 1959; Oliva and Cittadini, 1966).
The site of metastases also may be a determining factor in the response to
cyclophosphamide therapy. Various authors (Burn, 1968; Edelstyn et al., 1968)
have confirmed a higher percentage response in the case of soft tissue tumour
compared to bone metastases. The response rate of metastases in viscera such
as lung or liver lies intermediately.
Finally, it is usually noted that the first course of treatment with a cytotoxis
agent is the most efficacious. With continued or repeated treatment, resistance
tends to develop in the tumour to the action of the same cytotoxic agent. This
applies both to intensive high dosage and to continuous low dosage forms of
therapy.
Protection against side effects
There is considerable difference of opinion as to whether concomitant corti-
costeroid or androgen administration can protect against the toxic effects of
cyclophosphamide.
It is thought that cyclophosphamide is biologically activated by the liver and
Hayakawa et al. (1969) have suggested the prednisolone can prevent this activa-
tion in rats. This has not so far been demonstrated in the human. According
to Kostanecki et al. (1966) concomitant corticosteroid therapy may partially
protect against the epilating effect of cyclophosphamide. The author has been
unable to confirm this with doses of30 mg. prednisolone daily givenfor 4to 8 weeks
following an initial high dose ofthis agent, although it is saidto applyto continuous
low dose therapy. Corticosteroid therapy will relieve pressure in the vicinity of
the tumour (Stoll, 1963) and is often given concurrently with cyclophosphamide
in the case of mediastinal or cerebral tumours. There is no evidence that it
protects either the leucopoietic tissue or the megakaryocytes against damage by
cyclophosphamide.
It is well established that androgens can induce stimulation of erythropoieis
even in late breast cancer (Kennedy, 1962). Biederman et al. (1966) have reported
that norandrostenolone (Decadurabolin) 25 mg. intramuscularly at 10 day
intervals protects against the leucopenia resulting from continuous cyclophos-
phamide therapy. The author has been unable to confirm such a protective
effect.
The use of a tourniquet around the scalp during cyclophosphamide injection
has been suggested in order to decrease the likelihood of loss of scalp hair
(Hennessy, 1966). There are differences ofopinion as to the efficacy ofthe proce-
dure. The same author noted the absence of scalp epilation after intraperitoneal
administration of cyclophosphamide, and this may be the result of the lower
blood concentration which follows the administration of cytotoxic agents by this
route.
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The administration of cyclophosphamide is said to be contra-indicated in the
presence of jaundice due to liver metastases (Betteridge, 1964). The presence
of liver enlargement due to metastases does not in itself contra-indicate cyclo-
phosphamide therapy, and the author has occasionally noted marked but
temporary regression in the sizeoftheliverfollowingcontinuous low dosage therapy
in cases of this type.
DISCUSSION
The likelihood of a tumour responding to cytotoxic therapy depends not only
on the local concentration ofthe agent, but also on the duration ofexposure to the
agent. It has been demonstrated for experimental tumours that the response
following a given dose of an agent by local arterial infusion, is greater than from
the same dose given intravenously. The principle has been confirmed clinically
in some tumours, in the increased proportion of responders seen following arterial
infusion or perfusion with a cytotoxic agent. The technique is applied more easily
in the case oftumours involving the limbs or the head and neck region, but several
attempts have been made recently to apply such a technique to breast cancer also
(Lentin et al., 1967).
The likelihood ofresponse by a tumour is also influenced by the length of time
that it is exposed to an agent, as prolonged exposure is more likely to find all the
cells ofa slowly dividing tumour in their most sensitive phase. Cyclophosphamide
is said to belong to the cycle-specific group of agents which are much more toxic
for proliferating cells than for resting cells (Bergsagel, 1969). If this is so, then a
short acting agent ofthis type will require repeated administration in the case ofa
slowly dividing tumour, to kill the maximum number of malignant cells in their
most sensitive phase.
Unfortunately, high local concentration and prolonged exposure are mutually
exclusive principles because of the limited tolerance of the host tissues. One
must either accept the high single dose, with the aim of high concentration in the
tumour, or the lower continuous maintenance dosage with the aim of prolonged
exposure time. The relative importance of local concentration and exposure
time in each patient for each agent depends on individual recovery factors, and
these must be considered separately for the tumour cells as for the host tissue
cells.
The relationship between the tissue recovery factors of host and tumour in the
cure of experimental tumours is estimated by the therapeutic index. This is
defined as the proportion between the smallest lethal dose (LD 5) and the safe
curative dose (CD 95). It is therefore an index of therapeutic safety, which has
TABLE II. The Therapeutic Index in the Cure of Yoshida Sarcoma in Rats
According to the Fractionation of Various Alkylating Agents Given Intra-
ienously (after Brock and Wilmanns, 1958)
Agent Daily Therapeutic
doses index
Cyclophosphamide 1 8- 5
4. 4-3
Nitrogen 1 22
Mustard oxide 4 . 2- 7
ThioTEPA 1 . 0 64
4 0-65
480CYCLOPHOSPHAMIDE DOSAGE IN BREAST CANCER
been shown to vary considerably between the various alkylating agents according
to the fractionation ofdosage. TableII shows that in the case ofYoshida sarcoma,
fractionation of cyclophosphamide dosage is a disadvantage as shown by a lower
therapeutic index. For nitrogen mustard oxide the therapeutic index is slightly
better as a result of fractionation of dosage, while for thioTEPA it is unchanged.
For obvious reasons we cannot establish such an index in the human, but if the
experimental observations could be applied to the human, it might decide the
advantage or otherwise offractionation for curative dosage by each agent.
Clinical observations confirm that the therapeutic index of different agents
varies with fractionation. However, we have noted above that in the palliation
of human mammary cancer by cyclophosphamide, the effect of fractionation is
not in agreement with the experimental finding noted in the previous paragraph.
It may lead to gross error to carry over into clinical practice, a method of dose
fractionation based on the therapeutic index of animal experiment.
The relative importance of dose concentration as against length of exposure
to an agent in clinical therapy is also unpredictable on theoretical grounds as the
metabolic disposal of the agent will determine its concentration under special
fractionation circumstances. The effect of fractionation on each agent therefore
needs to be evaluated clinically not only for different tumours, but also for palli-
ative as well as curative purposes. As mentioned above, high dosage therapy may
be indicated to achieve dramatic regression of a rapidly growing but localized
tumour, because of the high local concentration of the agent over a short period.
If the disease is generalized however, the risks outweigh the advantage, and there
is no evidence that the likelihood of tumour regression in breast cancer is any
greater from intermittent high dosage of cyclophosphamide than from continuous
low dose therapy. The mean duration of tumour remission is generally less than
6 months in either case.
"Is toxicity really necessary?
There exists among clinicians practising cytotoxic chemotherapy a wide-
spread belief which is typified by the following opinion
"Some patients will be
lucky enough to respond to doses well below the limit of marrow tolerance, but
more will respond if the dose is pushed up as nearly as possible to that limit
"
(Porter, 1962). In a review with this paragraph's title, Bross et al. (1966) consid-
ered the evidence for the belief that substantial toxicity in the host will be associ-
ated with a higher proportion of tumour palliation by cytotoxic agents. They
analysed the data from 956 patients receiving 5-fluorouracil, mitomycin C,
AB 132, chlorambucil, or 6-mercaptopurine in the treatment of various types of
tumour.
Based upon the criterion of 5000 reduction in tumour size, Bross found that the
proportion of responders was no higher among patients exhibiting signs of marrow
toxicity (leucopenia below 2000 per c. mm. or thrombopenia below 100,000 per
c. mm.), than among those with evidence oflesser toxicity. A similar observation
had been made previously in the specific case of cyclophosphamide therapy in
breast or ovarian cancer (Coggins et al., 1961) and of thioTEPA therapy in breast
cancer (Lyons and Edelstyn, 1962). The author (Stoll, 1962) had suggested a
similar observation in therapy by various alkylating agents in cancers of the
breast, lung or ovary.
In cytotoxic therapy aiming at cure in the case ofchemroresistant neoplasms, it
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is likely that the best results will be achieved when the tumour cells are exposed
to the maximum amount of drug which can be tolerated by the marrow. Yet
there is no evidence that this likelihood applies to the palliation of tumours,
particularly moderately chemosensitive tumours such as those of the breast, lung
andovary.
This observation can be explained on a theoretical basis by the assumption
that even with tumours which are histologically indistinguishable, the chemo-
sensitivity ofanyparticulartumourto a given concentration ofa cytotoxic agent is
an individual function ofthe cells ofthat tumour (Druckrey, 1957). The differing
sensitivities shown by individual tumours ofthe same group will then conform to
the basic " law of individual variation " (Fig. 1). This law suggests that the
majority of tumours will show average sensitivity, a minority will show marked
susceptibility, and a further minority will show marked resistance.
NUMBER C
SENSITIVE
TUMOUJRS
ONE GROL
DRUG CONCENTRATION REQUIRED FOR
THERAPEUTIC EFFECT
FIG. 1.-Diagram to illustratelawofindividual variation asapplied to therangeofsensitivity
to chemotherapy of different members of one tumour type.
If we consider Fig. 1, and assume a tumour type where 50% of the members
are known to respond to a specific agent, we note that the chemosensitive members
lie to the left ofthe midline. Those tumours on the extreme left, i.e. inthe highly
susceptible area, will show regression from very low drug concentrations, with
almost no associated toxic effects. Those tumours in the middle ofthe curve will
respond to moderate drug concentrations. If the slope is low around the middle
ofthe curve, then increase ofthe dose even to near lethal levels could yield only a
very small increase in the proportion of tumour responding, but will lead to a
considerable increase in toxicity because of the chemosensitivity of haemopoietic
tissue. A small increase in response rate may be undetectable especially if it is
mainly at a subclinical level (see introductory section).
The clinician must ask himselfbefore initiating cytotoxic therapy in a patient
with cancer whether treatment can possibly cure, or whether it is for palliative
purposes. Ifit is for the latter reason, then the likelihood and degree ofpossible
benefit must outweigh the likelihood and degree of possible morbidity from that
specifictherapy.
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